- Home
- Publications
- Publication Search
- Publication Details
Title
Direct cardiovascular effects of glucagon like peptide-1
Authors
Keywords
Liraglutide, Exenatide, Sitagliptin, Vildagliptin, Saxagliptin
Journal
Diabetology & Metabolic Syndrome
Volume 5, Issue 1, Pages 47
Publisher
Springer Nature
Online
2013-09-03
DOI
10.1186/1758-5996-5-47
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a
- (2013) Craig W. Younce et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- A gut-heart connection in cardiometabolic regulation
- (2013) Alessia Buglioni et al. NATURE MEDICINE
- Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
- (2012) Harshal R. Patil et al. AMERICAN JOURNAL OF CARDIOLOGY
- Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment
- (2012) Zhenhua Dong et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
- (2012) Daisuke Shiraishi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
- (2012) Aaron S Kelly et al. Cardiovascular Diabetology
- Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions
- (2012) Toshimasa Shigeta et al. CIRCULATION
- A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity
- (2012) Mohammad Hossein Noyan-Ashraf et al. CIRCULATION
- Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe −/− mice
- (2012) F. Vittone et al. DIABETOLOGIA
- Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
- (2012) D. Nathanson et al. DIABETOLOGIA
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism
- (2012) Limei Liu et al. HYPERTENSION
- Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: The EXAMI study
- (2012) Flip J.P. Bernink et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Sitagliptin Exerts an Antinflammatory Action
- (2012) Antoine Makdissi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells
- (2011) Li Ding et al. ACTA PHARMACOLOGICA SINICA
- The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury
- (2011) Yumei Ye et al. BASIC RESEARCH IN CARDIOLOGY
- Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury
- (2011) Hiromasa Goto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
- (2011) Meimei Yin et al. Cardiovascular Diabetology
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- Forecasting the Future of Cardiovascular Disease in the United States
- (2011) Paul A. Heidenreich et al. CIRCULATION
- A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in Humans
- (2011) Philip A. Read et al. Circulation-Cardiovascular Interventions
- GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats
- (2011) Lin Wu et al. CLINICAL SCIENCE
- Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers
- (2011) Y.-L. He et al. CURRENT MEDICAL RESEARCH AND OPINION
- Brain GLP-1 Signaling Regulates Femoral Artery Blood Flow and Insulin Sensitivity Through Hypothalamic PKC-
- (2011) C. Cabou et al. DIABETES
- Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies
- (2011) Steven P Marso et al. Diabetes & Vascular Disease Research
- The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance" to Glucagon-Like Peptide 1 in Diabetes
- (2011) A. Ceriello et al. DIABETES CARE
- Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
- (2011) M. Nagashima et al. DIABETOLOGIA
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure
- (2011) Nelson Gomez et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
- (2011) Philip A Read et al. HEART
- Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents
- (2011) B. B. Dokken et al. HORMONE AND METABOLIC RESEARCH
- Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy
- (2011) Arpita Kalla Vyas et al. PLoS One
- Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes
- (2011) Susumu Ogawa et al. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
- Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
- (2010) Mads Halbirk et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A
- (2010) Hisko Oeseburg et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
- (2010) Que Liu et al. Cardiovascular Diabetology
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase–Mediated, Nitric Oxide–Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy
- (2010) Siva Bhashyam et al. Circulation-Heart Failure
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
- (2010) M. Asmar et al. DIABETES
- The synthetic GLP-I receptor agonist, exenatide, reduces intimal hyperplasia in insulin resistant rats
- (2010) Subramanyam N. Murthy et al. Diabetes & Vascular Disease Research
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
- (2010) W. Yang et al. DIABETES OBESITY & METABOLISM
- Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
- (2010) Kiwon Ban et al. ENDOCRINOLOGY
- Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis
- (2010) Hans D. Theiss et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats
- (2010) Bruna PM Pacheco et al. JOURNAL OF HYPERTENSION
- Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
- (2010) Mary Parks et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction
- (2010) Betsy B. Dokken et al. RESUSCITATION
- GIP: No Longer the Neglected Incretin Twin?
- (2010) R. N. Kulkarni Science Translational Medicine
- Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
- (2009) T. Okerson et al. AMERICAN JOURNAL OF HYPERTENSION
- Incretin Therapies: Effects Beyond Glycemic Control
- (2009) Sunder Mudaliar et al. AMERICAN JOURNAL OF MEDICINE
- Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model
- (2009) Kunio Hirata et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
- (2009) Yuji Ishibashi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes
- (2009) C. W. Chia et al. DIABETES
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects
- (2009) Daniel M. Bloomfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes
- (2009) Dhruba J. Chatterjee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
- (2009) Hongbin Liu et al. JOURNAL OF ENDOCRINOLOGY
- Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
- (2009) Leo Timmers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome
- (2009) Kevin D. Laugero et al. Metabolic Syndrome and Related Disorders
- Incretin-based therapies for type 2 diabetes mellitus
- (2009) Julie A. Lovshin et al. Nature Reviews Endocrinology
- Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
- (2009) E.J. Verspohl PHARMACOLOGY & THERAPEUTICS
- GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP
- (2008) Brian D. Green et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat
- (2008) Indu Poornima et al. Circulation-Heart Failure
- Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity
- (2008) C. Cabou et al. DIABETES
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started